

REFERENCES

- [1] Australian National Audit Office. Selected measures for managing subsidised drug use in the pharmaceutical benefits scheme. Sydney, NSW, Australia: Department of Health and Ageing; 2006.
- [2] Medicare Services Advisory Committee. Endoluminal grafting for abdominal aortic aneurysm. Application 1006. Canberra, ACT, Australia: Department of Health and Ageing; 2006.
- [3] Medical Services Advisory Committee (MSAC). MSAC brochure. Canberra, ACT, Australia: Department of Health and Ageing; 2007.
- [4] Carlson JJ, Garrison LP, Jr., Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. *J Manag Care Pharm* 2009;15:683–7.
- [5] Carlson JJ, Sullivan SD, Garrison LP, et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. *Health Policy* 2010;96:179–90.
- [6] Mohr PE, Tunis SR. Access with evidence development: the US experience. *Pharmacoeconomics* 2010;28:153–62.
- [7] Towse A, Garrison LP, Jr. Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. *Pharmacoeconomics* 2010;28:93–102.
- [8] Trueman P, Grainger DL, Downs KE. Coverage with evidence development: applications and issues. *Int J Technol Assess Health Care* 2010;26:79–85.
- [9] Włodarczyk J, Cleland L, Keogh A, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension (PAH) in Australia: cost-effectiveness and risk sharing. *Pharmacoeconomics* 2006;24:903–15.
- [10] Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet* 2001;358:1119–23.
- [11] Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med* 2002;346:896–903.
- [12] Owen A, Spinks J, Meehan A, et al. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian pharmaceutical benefits scheme: the bosentan patient registry. *J Med Econ* 2008;11:235–43.
- [13] Keogh A, Strange G, McNeil K, et al. The bosentan patient registry: long-term survival in pulmonary arterial hypertension. *Intern Med J* 2011;41:227–34.
- [14] McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. *Eur J Clin Invest* 2006;36(Suppl 3):10–5.
- [15] Kawut SM, Taichman DB, Archer-Chicko CL, et al. Haemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. *Chest* 2003;123:344–50.
- [16] Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. *Br J Rheumatol* 1996;35:989–93.
- [17] Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. *Pharmacoeconomics* 2008;26:551–6.
- [18] Pollack A. Pricing pills by the result. *The New York Times*. July 14, 2007. Available from: <http://www.nytimes.com/2007/07/14/business/14drugprice.html?ex=1342065600&en=e0184d170e89d16d&ei=5090&partner=rssuserland&emc=rss> [Accessed April 19, 2011].

ERRATUM

The article “Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT),” by Briel et al. was published in *Value in Health* 2011;14:450–7. The correct author by-line is as follows: The SPRINT Investigators. The full listing of the SPRINT Investigators who took part in the collaboration of this article can be found in the Acknowledgments section of the article.

ERRATUM

The article “Economic Impact of Nonpersistence with Antidepressant Treatment in the Adult Population of Quebec: A Comparative Cost-Effectiveness Approach,” by Béland et al (*Value in Health* 2011;14:492–8), was published with an incorrect [Figure 1](#). The correct [Figure 1](#) is shown below.




Fig. 1 – Mean total costs and effectiveness of alternative antidepressant treatment.